Socioeconomic inequalities in prevalence, awareness, treatment and control of hypertension: evidence from the PERSIAN cohort study.
Awareness
Control
Hypertension
Inequality
PERSIAN Cohort
Treatment
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
22 07 2022
22 07 2022
Historique:
received:
08
11
2021
accepted:
17
05
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Elevated blood pressure is associated with cardiovascular disease, stroke and chronic kidney disease. In this study, we examined the socioeconomic inequality and its related factors in prevalence, Awareness, Treatment and Control (ATC) of hypertension (HTN) in Iran. The study used data from the recruitment phase of The Prospective Epidemiological Research Studies in IrAN (PERSIAN). A sample of 162,842 adults aged > = 35 years was analyzed. HTN was defined according to the Joint National Committee)JNC-7(. socioeconomic inequality was measured using concentration index (Cn) and curve. The mean age of participants was 49.38(SD = ± 9.14) years and 44.74% of the them were men. The prevalence of HTN in the total population was 22.3%(95% CI: 20.6%; 24.1%), and 18.8%(95% CI: 16.8%; 20.9%) and 25.2%(95% CI: 24.2%; 27.7%) in men and women, respectively. The percentage of awareness treatment and control among individuals with HTN were 77.5%(95% CI: 73.3%; 81.8%), 82.2%(95% CI: 70.2%; 81.6%) and 75.9%(95% CI: 70.2%; 81.6%), respectively. The Cn for prevalence of HTN was -0.084. Two factors, age (58.46%) and wealth (32.40%), contributed most to the socioeconomic inequality in the prevalence of HTN. The prevalence of HTN was higher among low-SES individuals, who also showed higher levels of awareness. However, treatment and control of HTN were more concentrated among those who had higher levels of SES, indicating that people at a higher risk of adverse event related to HTN (the low SES individuals) are not benefiting from the advantage of treatment and control of HTN. Such a gap between diagnosis (prevalence) and control (treatment and control) of HTN needs to be addressed by public health policymakers.
Sections du résumé
BACKGROUND
Elevated blood pressure is associated with cardiovascular disease, stroke and chronic kidney disease. In this study, we examined the socioeconomic inequality and its related factors in prevalence, Awareness, Treatment and Control (ATC) of hypertension (HTN) in Iran.
METHOD
The study used data from the recruitment phase of The Prospective Epidemiological Research Studies in IrAN (PERSIAN). A sample of 162,842 adults aged > = 35 years was analyzed. HTN was defined according to the Joint National Committee)JNC-7(. socioeconomic inequality was measured using concentration index (Cn) and curve.
RESULTS
The mean age of participants was 49.38(SD = ± 9.14) years and 44.74% of the them were men. The prevalence of HTN in the total population was 22.3%(95% CI: 20.6%; 24.1%), and 18.8%(95% CI: 16.8%; 20.9%) and 25.2%(95% CI: 24.2%; 27.7%) in men and women, respectively. The percentage of awareness treatment and control among individuals with HTN were 77.5%(95% CI: 73.3%; 81.8%), 82.2%(95% CI: 70.2%; 81.6%) and 75.9%(95% CI: 70.2%; 81.6%), respectively. The Cn for prevalence of HTN was -0.084. Two factors, age (58.46%) and wealth (32.40%), contributed most to the socioeconomic inequality in the prevalence of HTN.
CONCLUSION
The prevalence of HTN was higher among low-SES individuals, who also showed higher levels of awareness. However, treatment and control of HTN were more concentrated among those who had higher levels of SES, indicating that people at a higher risk of adverse event related to HTN (the low SES individuals) are not benefiting from the advantage of treatment and control of HTN. Such a gap between diagnosis (prevalence) and control (treatment and control) of HTN needs to be addressed by public health policymakers.
Identifiants
pubmed: 35864469
doi: 10.1186/s12889-022-13444-x
pii: 10.1186/s12889-022-13444-x
pmc: PMC9306154
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1401Informations de copyright
© 2022. The Author(s).
Références
Int J Epidemiol. 2014 Oct;43(5):1563-77
pubmed: 24867304
BMC Public Health. 2020 Feb 11;20(1):214
pubmed: 32046684
PLoS One. 2014 Jan 23;9(1):e86043
pubmed: 24465859
J Educ Health Promot. 2018 Apr 03;7:45
pubmed: 29693026
Sci Rep. 2019 Dec 13;9(1):19098
pubmed: 31836764
BMJ Open. 2019 Mar 13;9(3):e025538
pubmed: 30867202
J Environ Public Health. 2012;2012:918368
pubmed: 22649464
J Hum Hypertens. 2019 Aug;33(8):613-625
pubmed: 30659279
J Cardiovasc Thorac Res. 2019;11(2):116-120
pubmed: 31384405
Hypertension. 2000 Mar;35(3):814-21
pubmed: 10720600
Health Econ. 2005 Apr;14(4):429-32
pubmed: 15495147
Glob J Health Sci. 2015 Apr 19;7(6):240-9
pubmed: 26153189
Clin Epidemiol. 2021 Sep 03;13:791-800
pubmed: 34512032
BMC Public Health. 2012 Jun 22;12:474
pubmed: 22726343
Sci Rep. 2019 Jul 29;9(1):10970
pubmed: 31358791
Eur J Clin Invest. 2019 Jul;49(7):e13124
pubmed: 31038733
J Prev Med Public Health. 2019 Mar;52(2):131-139
pubmed: 30971080
Arch Iran Med. 2017 Nov 01;20(11):691-695
pubmed: 29480734
Am J Epidemiol. 2018 Apr 1;187(4):647-655
pubmed: 29145581
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Int J Epidemiol. 2013 Oct;42(5):1410-26
pubmed: 23563358
Int J Hypertens. 2011;2011:132405
pubmed: 21747971
Lancet. 2019 Aug 24;394(10199):639-651
pubmed: 31327564
Iran J Public Health. 2011;40(3):63-70
pubmed: 23113087
Sleep Health. 2019 Oct;5(5):509-513
pubmed: 31302069
Soc Sci Med. 1991;33(5):545-57
pubmed: 1962226
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
Cad Saude Publica. 2003 May-Jun;19(3):817-27
pubmed: 12806484
PLoS One. 2016 Aug 24;11(8):e0160922
pubmed: 27556532
Hypertension. 2008 Apr;51(4):952-9
pubmed: 18259027
J Epidemiol. 2012;22(5):425-32
pubmed: 22785247
J Hypertens. 1984 Aug;2(4):361-6
pubmed: 6530546
BMC Public Health. 2016 Jan 27;16:82
pubmed: 26817835
Clin Exp Hypertens. 2009 Feb;31(1):64-70
pubmed: 19172460
BMC Public Health. 2016 Jun 10;16:492
pubmed: 27286953
Lancet. 2008 Nov 8;372(9650):1661-9
pubmed: 18994664
Curr Hypertens Rep. 2019 Apr 4;21(4):27
pubmed: 30949774
JAMA. 2012 Mar 28;307(12):1273-83
pubmed: 22427615
Int J Equity Health. 2017 Jul 1;16(1):27
pubmed: 28666448
JAMA Netw Open. 2021 Aug 2;4(8):e2121443
pubmed: 34410395
Lancet. 1990 Apr 7;335(8693):827-38
pubmed: 1969567
East Mediterr Health J. 2004 May;10(3):406-15
pubmed: 16212218
Am J Hypertens. 2020 Jan 1;33(1):84-91
pubmed: 31420642
Sci Rep. 2019 Aug 27;9(1):12409
pubmed: 31455810
Rev Port Cardiol (Engl Ed). 2019 Aug;38(8):547-555
pubmed: 31708247